A latest study, jointly conducted by the Chinese and UK scientists, has shown that treatment of heart attack patients with Plavix Clopidogrel, a new anti-platelet drug, can noticeably reduce the mortality and recurrence. The new therapeutic technique is low in cost and simple in application.
The joint project, with the participation of over 1200 hospitals headed by the Oxford University and Fuwai Hospital affiliated to the Chinese Academy of Medical Sciences, has involved in clinical treatment of some 46,000 acute heart attack patients in 5 years. Scientists found that an addition of Plavix Clopidogrel at a 75mg dosage to the conventional aspirin and other related therapeutic processes could noticeably reduce the mortality from the disease. Having designed to avoid serious hemorrhage, the therapeutic addition can also bring down the risks of recurrence and stroke occurrence by 15%. With numerous merits including limited side effects, lower costs, and proven effects, the new approach expects to benefit more heart attack patients in the world. Some international medical organizations, including the American Institute of Cardiology and the European Society of Cardiology, have accepted the finding and listed it in their respective guidebooks for heart attack treatment. |
